{
    "nct_id": "NCT05844501",
    "official_title": "Inhibition of Small Conductance Calcium-Activated Potassium Current: A New Therapeutic Approach for Atrial Fibrillation",
    "inclusion_criteria": "* Men and women 18-100 years of age\n* ECG-verified AF and/or atrial flutter requiring elective catheter ablation\n* Receiving guideline-recommended anticoagulation (if CHA2DS2-VASc score is 0 (men) or 1 (women), anticoagulation can be omitted)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Women of childbearing potential\n* Subject reported syncope of unknown origin within the previous 6 months\n* Diagnosis of active thyrotoxicosis\n* Diagnosis AF from reversible noncardiac causes\n* Diagnosis of acutely decompensated heart failure\n* Left ventricular ejection fraction less than or equal to 20%\n\n  * New York Heart Association class IV heart failure\n  * Diagnosis of severe liver disease (Child-Pugh score greater than or equal to 10)\n* Cardiac surgery (preceding 2 months)\n* Not receiving anticoagulation due to contraindications (as determined by treating physician and recorded in the medical record)\n* Pretreatment QRS > 180 ms, QTc > 450 ms within two weeks of screening visit\n* Heart rate < 50 beats per minute in SR\n* Diagnosis of hypotension\n* Diagnosis of Wolff-Parkinson-White syndrome\n* Previous ondansetron hypersensitivity or serotonin syndrome\n* Diagnosis of phenylketonuria\n* Diagnosis of congenital long QT syndrome\n* Concomitant therapy with both beta-blockers and a nondihydropyridine CCB\n* History of drug-induced torsades de pointes or QTc prolongation\n* Concomitant therapy with QTc-prolonging medications (www.crediblemeds.org), except amiodarone and propafenone\n* Concomitant therapy with serotonergic drugs (selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, lithium, tramadol), apomorphine, phenytoin, carbamazepine, oxcarbazepine, rifampin.\n* Left ventricular ejection fraction < 20% and those with NYHA class IV heart failure with reduced ejection fraction (confirmed by diagnosis or echocardiogram within 6 months of enrollment in screening)\n* Patients with pre-existing allergies to adhesives\n* Patients with neuromuscular stimulators",
    "miscellaneous_criteria": ""
}